GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » C-Rad AB (LTS:0R44) » Definitions » EV-to-EBIT

C-Rad AB (LTS:0R44) EV-to-EBIT : 23.54 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is C-Rad AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, C-Rad AB's Enterprise Value is kr1,346.7 Mil. C-Rad AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr57.2 Mil. Therefore, C-Rad AB's EV-to-EBIT for today is 23.54.

The historical rank and industry rank for C-Rad AB's EV-to-EBIT or its related term are showing as below:

LTS:0R44' s EV-to-EBIT Range Over the Past 10 Years
Min: -1055.28   Med: -11.64   Max: 862.52
Current: 23.54

During the past 13 years, the highest EV-to-EBIT of C-Rad AB was 862.52. The lowest was -1055.28. And the median was -11.64.

LTS:0R44's EV-to-EBIT is ranked worse than
60.36% of 449 companies
in the Medical Devices & Instruments industry
Industry Median: 19.58 vs LTS:0R44: 23.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. C-Rad AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr1,275.9 Mil. C-Rad AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr57.2 Mil. C-Rad AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.48%.


C-Rad AB EV-to-EBIT Historical Data

The historical data trend for C-Rad AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C-Rad AB EV-to-EBIT Chart

C-Rad AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -139.27 88.91 49.12 53.36 29.20

C-Rad AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.25 24.38 23.72 29.20 22.72

Competitive Comparison of C-Rad AB's EV-to-EBIT

For the Medical Devices subindustry, C-Rad AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C-Rad AB's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where C-Rad AB's EV-to-EBIT falls into.



C-Rad AB EV-to-EBIT Calculation

C-Rad AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1346.655/57.197
=23.54

C-Rad AB's current Enterprise Value is kr1,346.7 Mil.
C-Rad AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr57.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C-Rad AB  (LTS:0R44) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

C-Rad AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=57.197/1275.92848
=4.48 %

C-Rad AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr1,275.9 Mil.
C-Rad AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr57.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C-Rad AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of C-Rad AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


C-Rad AB (LTS:0R44) Business Description

Traded in Other Exchanges
Address
Sjukhusvägen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. The operating segments of the group are the Positioning segment which includes development and sales of products in the field of patient positioning during radiotherapy, including catalyst, sentinel, and HIT lasers; and the Imaging segment which includes the development of imaging devices and detectors for cancer treatments and dosimetry. It generates maximum revenue from the Positioning segment. The firm sells its products in Sweden and internationally.

C-Rad AB (LTS:0R44) Headlines

No Headlines